Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
April 20, 2009
- OHARA to Improve Tablet Distinguishability by ID Printing on Both Sides of Tablet
April 20, 2009
- So-net M3 Survey Shows Physicians Depend on Internet for Information
April 20, 2009
- JPDSC to Construct PGx Database for the Japanese
April 20, 2009
- GENERICS NEWS IN BRIEF
April 20, 2009
- MIN-IREN Protests against MTPC for Data Falsification
April 20, 2009
- Wyeth Files BLA for Prevnar 13 in US
April 20, 2009
- % of Prescriptions Allowing Generic Substitution Down to 52%: Nihon Chouzai
April 20, 2009
- 40 Medical Bills for Zyprexa Rejected due to Problems such as Overdoses
April 20, 2009
- Soaring Medical Expenses Are Mainly due to Drugs: Dr Nakagawa
April 20, 2009
- Some Med Facilities Do Not Apply for KRAS Gene Test as Senshin-Iryo
April 20, 2009
- Additional Economic Stimulation Measures Target Unapproved Drugs
April 20, 2009
- Lifestyle Intervention May Be as Effective as Medication in Japanese with Early Diabetes: DIANA Study
April 20, 2009
- CDFS to Review Japan's First Ca Blocker + ARB Combination
April 20, 2009
- Council on Regulatory Reform Calls For Continued Permission of Online Sale of OTC Drugs
April 20, 2009
- 20% of Hospitals in Shiga Pref. Prohibit Use of Generics as a Rule
April 20, 2009
- Kowa, Apo Plus Station Creates "Career & Leaps" to Support Marketing of OTC Drugs
April 20, 2009
- Kissei's Urief Launched in the US
April 20, 2009
- Alpha MOS Sets Up Japanese Subsidiary
April 20, 2009
- Daiichi Sankyo, Eli Lilly Launch Prasugrel in UK
April 20, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…